Appendix: external initiatives and membership of associations

GRI 102-12: External initiatives

  • Joined Access Accelerated, a global initiative to advance access to treatment and care for chronic diseases in lower-income countries
  • Joined Global Chagas Disease Coalition
  • Signatory to the London Declaration on Neglected Tropical Diseases
  • Member of the Swiss Alliance against Neglected Tropical Diseases
  • Signatory to the Davos Declaration on Combating Antimicrobial Resistance (AMR)
  • Committed to the Industry Roadmap for Progress on Combating AMR
  • Joined the AMR Industry Alliance
  • Joined the AMR Action Fund, an industry initiative
  • Joined the Responsible Antibiotics Manufacturing Platform
  • Joined Business Refugee Action Network
  • Founding member of the Value Balancing Alliance, which aims to develop a standard model for measuring and disclosing the environmental, human, social and financial value a company provides
  • Member of the Impact Valuation Roundtable
  • Joined the United Nations Equal Pay International Coalition (EPIC)
  • Signatory to the Women’s Empowerment Principles launched by the UNGC and the UN Development Fund for Women (UNIFEM)
  • As a signatory to the UNGC, Novartis supports the Universal Declaration of Human Rights, the ILO’s Declaration on Fundamental Principles and Rights at Work, the Rio Declaration on Environment and Development, the UN Convention Against Corruption, the Organization for Economic Cooperation and Development (OECD) Guidelines for Multinational Enterprises, the OECD Convention on Combating Bribery of Foreign Public Officials, and the UN Guiding Principles on Business and Human Rights
  • Signatory to the World Business Council for Sustainable Development’s CEO Guide to Human Rights
  • Support for the United Nations’ workplace standards protecting the rights of lesbian, gay, bisexual, transgender and intersex people
  • Signatory to the International Chamber of Commerce’s Business Charter for Sustainable Development
  • Signatory to the ILO Tripartite Declaration of Principles Concerning Multinational Enterprises and Social Policy
  • Signatory to the CEO Letter on the UN Convention Against Corruption
  • Signatory to the Partnering Against Corruption Initiative (PACI), a World Economic Forum initiative
  • Support for the Pharmaceutical Industry Principles for Responsible Supply Chain Management set by the Pharmaceutical Supply Chain Initiative (PSCI)
  • Support for the Task Force on Climate-related Financial Disclosures (TCFD)
  • Joined Sustainability 30 (S30), a group of sustainability executives from 30 of the world’s leading companies working to accelerate business action on sustainability
  • Signatory to the UN Global Compact’s CEO Water Mandate
  • Joined IMI-PREMIER (Prioritization and Risk Evaluation of Medicines in the Environment)
  • Voluntarily agreed to reduce greenhouse gas (GHG) emissions in line with the Paris Agreement and subsequent international target commitments, such as those of the European Union (GHG emissions are reported according to the GHG Protocol)
  • Signatory to the UNGC/UNEP/World Business Council for Sustainable Development (WBCSD) initiative Caring for Climate: The Business Leadership Platform, also fulfilling the Business Leadership Criteria on Carbon Pricing
  • Classify and dispose of waste according to the Basel Convention on the Control of Transboundary Movements of Hazardous Wastes and Their Disposal
  • Member of the Carbon Disclosure Project, Water Disclosure Project and Supply Chain Disclosure Project
  • Signatory to WBCSD’s Manifesto for Energy Efficiency in Buildings
  • Signatory to the Guiding Principles on Access to Healthcare (GPAH), which frame the pharmaceutical industry’s approach to expanding access to quality healthcare globally
  • Strategic partner of the World Economic Forum

GRI 102-13: Membership of associations

Novartis Group companies are members of various chambers of commerce, sustainability industry associations and pharmaceutical industry associations.

We work closely with trade associations, which create opportunities to raise industry standards and exchange best practices.

Novartis is a member of:

  • Interpharma, Intergenerika scienceindustries, economiesuisse, and SwissHoldings in Switzerland
  • Pharmaceutical Research and Manufacturers of America (PhRMA), the Biotechnology Innovation Organization (BIO), Association for Accessible Medicines (AAM), AdvaMed in the US
  • Global and regional associations, including the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), Alliance for Regenerative Medicines (ARM)
  •  European Federation of Pharmaceutical Industries and Associations (EFPIA), EuropaBio, Medicines for Europe, EUCOPE, MedTech in the EU
  • National associations in most markets where Novartis has a legal subsidiary